Please check your internet connection and try again.
# Hyoscine Butylbromide (Scopolamine Butylbromide)
## Overview
A quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it has limited CNS penetration due to its chemical structure, resulting in fewer central anticholinergic side effects. It acts as an antimuscarinic agent on smooth muscle cells in the GI, biliary, and urinary tracts.
## Primary Indications
* Relief of smooth muscle spasms (GI/biliary/genitourinary).
* Adjunct in diagnostic procedures (e.g., endoscopy/radiology).
* Palliative care (management of respiratory secretions/“death rattle”).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum: 100 mg/day (varies by local protocol).
* **IV/IM/SC:** 20 mg as a single dose; may repeat every 30 minutes if needed. Maximum: 100 mg/day.
* **Palliative Care (Continuous SC Infusion):** Typically 60–120 mg/day depending on clinical suppression of secretions.
## Pediatric Dosing
* **Children (6–12 years):** 10 mg three times daily (oral).
* **Note:** Not routinely recommended for children under 6 years. Use in pediatrics should follow local institutional guidelines strictly.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized dose reduction guidelines exist; however, use with caution due to decreased clearance. Use lower doses and monitor for accumulation.
* **Elderly:** Use lower starting doses; increased risk of anticholinergic side effects (urinary retention, constipation, cognitive impairment).
## Contraindications
* Hypersensitivity to hyoscine or excipients.
* Myasthenia gravis.
* Megacolon.
* Mechanical intestinal obstruction (e.g., pyloric stenosis, paralytic ileus).
* Narrow-angle glaucoma (untreated).
* Tachycardia/tachydysrhythmia.
## Adverse Effects
* **Common:** Dry mouth, visual accommodation disturbances (blurred vision), tachycardia, constipation.
* **Serious:** Urinary retention, anaphylaxis, acute angle-closure glaucoma (in predisposed patients).
## Key Drug Interactions
* **Anticholinergics:** Synergistic effects (e.g., TCAs, antihistamines, antipsychotics, amantadine) increase risk of toxicity.
* **Dopamine Antagonists:** May result in physiological antagonism of effects on GI motility (e.g., metoclopramide or domperidone effect may be reduced).
* **Tachycardia-inducing agents:** Beta-agonists or quinidine may exacerbate tachycardia.
## Monitoring
* Monitor heart rate (especially with parenteral use).
* Assess for relief of spasm or symptom control.
* Monitor for signs of urinary retention or ocular pain.
## Clinical Pearls
* **Formulation Warning:** Hyoscine butylbromide is poorly absorbed from the GI tract (bioavailability <10%); parenteral routes are significantly more potent.
* **Palliative Utility:** Widely used off-label in hospice care to dry bronchial secretions; however, it does not act on existing secretions, only prevents new accumulation.
* **Systemic Absorption:** While it crosses the blood-brain barrier less than tertiary amines, patients with pre-existing cognitive impairment may still be sensitive to central effects.
***
*Disclaimer: This information is for educational purposes only. Clinical practice varies by jurisdiction and local institutional protocols. Always verify current prescribing information, contraindications, and dosing with local formularies and pharmacist consultation before administration.*
